title: Transcatheter arterial infusion chemotherapy increases expression level of miR-142-5p in stage III colorectal cancer.
abstract: OBJECTIVE
  To investigate the expression level of miR-142-5p and its potential target gene endothelial PAS domain protein 1(EPAS1) in Stage III colorectal cancer during Transcatheter arterial infusion chemotherapy (TAI).
  
  
  METHODS
  Illumina high-throughput sequencing was used to obtain miRNA expression profiles of paired tumor and adjacent normal tissues from one patient received TAI 1 week before the operation and another patient directly underwent an operation. The expression levels of miR-142-5p was measured with both high-throughput sequencing and quantitative real time-polymerase chain reaction.
  
  
  RESULTS
  The expression levels of miR-142-5p, were significantly reduced in tumor tissues of stage III CRC, then significantly increased in tumor tissues receiving TAI and higher than tumor tissues without TAI. The apoptosis rate of HT-29 colon cancer cells was mildly increased after transfection with pre-miR-142. miR-142-5p could bind directly to the 3'untranslated region of endothelial PAS domain protein 1 and reduce its expression.
  
  
  CONCLUSIONS
  miR-142-5p is a potential tumor suppressor in CRC and is upregulated in tumor tissues after TAI, suggesting its potential clinical values for testing the functionality of TAI and predicting the progress of CRC.
authors.forename: D
authors.initials: D
authors.lastname: Shi
authors.affiliation: Department of Interventional Oncology, Renji Hospital Shanghai Jiaotong University School of Medicine,160 Pujian Rd., Pudong, Shanghai 200127, China.
authors.forename: B
authors.initials: B
authors.lastname: Zhai
authors.forename: Y
authors.initials: Y
authors.lastname: Zheng
authors.forename: R
authors.initials: R
authors.lastname: Ren
authors.forename: M
authors.initials: M
authors.lastname: Han
authors.affiliation: Shanghai Institute of Medical Image Research, 180 Fenglin Rd., Shanghai 200032, China.
authors.forename: X
authors.initials: X
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016461:Chemoembolization, Therapeutic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D014408:Biomarkers, Tumor; C555159:MIRN142 microRNA, human; D035683:MicroRNAs